Effects of Sea Buckthorn Oil on Dry Eye

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00739713

Acronym

DESB

Enrollment

100

Registered

2008-08-22

Start date

2008-09-30

Completion date

2009-03-31

Last updated

2018-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndromes

Keywords

dry eye, sea buckthorn, Hippophaë

Brief summary

The objective is to study the effect of sea buckthorn oil on dry eye.

Detailed description

The objective is to study whether regular consumption of sea buckthorn berry oil can relieve the symptoms of dry eye syndrome. The study design is a parallel randomized double-blind placebo controlled trial. The participants daily consume sea buckthorn or placebo oil for 3 months. The dry eye symptoms will be monitored during the study using a validated questionnaire. In addition clinical dry eye tests are made by an ophthalmologist three time during the study. Samples will be taken for tear film lipid and cytokine analyses. Blood samples for the analyses of inflammatory markers are also obtained. The cytokine and other inflammation marker analyses are optional. The symptoms will be monitored and clinical tests made also 4 weeks after the participants have stopped consuming the study oils.

Interventions

DIETARY_SUPPLEMENTSea buckthorn (Hippophaë rhamnoides) oil

Dosage 2 g/d, frequency twice/d, duration 3 months

DIETARY_SUPPLEMENTPlacebo comparison

Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Dry eye symptoms

Exclusion criteria

* Severe illness * Anticholinergic drugs * Smoking

Design outcomes

Primary

Measure	Time frame
Symptom severity: symptom questionnaires and clinical dry eye tests	3 months intervention + 1 month after the intervention

Secondary

Measure	Time frame
Tear film lipid profile, tear cytokines, inflammation mediators in blood	3 months intervention + 1 month after the intervention

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026